我國計劃將更多抗癌藥納入醫保

China will make more cancer drugs affordable, as a new round of negotiations between the country's state medical insurance administration and pharmaceutical companies to add such drugs to the medical insurance list is scheduled to finish by the end of September.
隨着國家醫療保障局和藥企展開新一輪抗癌藥醫保準入談判，我國將使更多抗癌藥能爲人們所負擔。談判工作預計將於9月底前完成。

The administration said it has selected a range of drugs to be added and is confirming the producers' willingness to further negotiate.
國家醫保局稱，已遴選一系列擬納入醫保的藥品，目前正與藥企確認進一步的談判意願。

All of these drugs are of great clinical value and will bring huge benefits to patients with different blood cancers or solid tumors, including colorectal cancer, renal cell carcinoma, lymphoma, and chronic myelogenous leukemia, said the administration.
該機構表示，所有擬談判的藥品均具有較高的臨牀價值，將爲患有結直腸癌、腎細胞癌、淋巴癌、多發性骨髓瘤等不同血液腫瘤或實體腫瘤的患者帶來極大的益處。

China has exempted import tariffs from all common drugs including cancer drugs, cancer alkaloid-based drugs, and imported traditional Chinese medicine since May 1.
自5月1日以來，中國已免除了包括抗癌藥在內的所有普通藥品、具有抗癌作用的生物鹼類藥品及有實際進口的中成藥的進口關稅。

Based on the new policy, 12 pharmaceutical companies have recalculated the prices of their products and will submit applications for price adjustments based on the requirements of the administration.
根據新政，12家藥企已對藥品價格進行重新測算，並將根據國家醫保局的要求提交藥價調整申請。

A negotiation launched in 2017 has lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.
於2017年啓動的一項談判，降低了15種療效確切但價格較爲昂貴的癌症治療藥品的價格，如赫普丁、利妥西單抗和硼替佐米，並將這些藥物添加到醫療保險報銷單中。